

CSD/BSE&NSE/BM/2024-25
September 19, 2024

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors of the Company (“Board”) at its meeting held today i.e., September 19, 2024, considered and took on record the following matters:

1. Mr. Vaidheesh Annaswamy (DIN: 01444303) has decided to step down from his role as Executive Chairperson and Director of the Company, effective from close of business hours on September 19, 2024. Consequently, he will cease to be Chairman of Corporate Social Responsibility Committee and Risk Management Committee; and member of the Stakeholder’s Relationship Committee, of the Board of Directors of the Company.

The Board placed on record its appreciation for the valuable contribution made by Mr. Vaidheesh Annaswamy during his tenure on the Board.

Mr. Vaidheesh Annaswamy will continue with the Company in advisory role as ‘Vice-Chairperson of Advisory Council’ to provide guidance as may be required by the Company from time to time.

The relevant details as required under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, along with his resignation letter are annexed herewith as ‘Annexure-1A and 1B’.

2. Approved the appointment of Mr. Vivek Sharma (DIN: 08559495) as an Additional Director and Executive Chairman of the Company, as recommended by the Nomination and Remuneration Committee, for a period of five years with effect from September 20, 2024, subject to approval of the shareholders through postal ballot process.

Mr. Vivek Sharma shall be based out of Boston (United States of America). He is also inducted and appointed as Chairman of the Corporate Social Responsibility Committee and Risk Management Committee; and member of the Stakeholder’s Relationship Committee, of the Board of Directors of the Company.

Mr. Vivek Sharma is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvенpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236

The relevant details as required under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, including profile of Mr. Vivek Sharma are annexed herewith as 'Annexure-2A and 2B'.

3. Pursuant to Regulation 30(5) of the SEBI Listing Regulations, approved revisions to the authorized Key Managerial Personnel for the purpose of determining materiality of an event or information and making disclosures thereof to the Stock Exchange(s). The "Policy for Determining Material Event or Information" ("Policy") in pursuance to Regulation 30 of the SEBI Listing Regulations, is also amended to reflect the above change under Regulation 30(5) of SEBI Listing Regulations. The changes will be effective from September 20, 2024:

Name	Designation	E-mail ID
Mr. Vivek Sharma	Executive Chairman (<i>effective from September 20, 2024</i>)	vsharma@suvенpharm.com
Dr. V Prasada Raju	Managing Director	drprasadaraju.v@suvенpharm.com
Dr. Sudhir Kumar Singh	Chief Executive officer	sudhirk.singh@suvенpharm.com
Mr. Himanshu Agarwal	Chief Financial Officer	himanshu.agarwal@suvенpharm.com
Mr. Kundan Kumar Jha	Company Secretary, Compliance Officer and Head-Legal	kundankumar.jha@suvенpharm.com
Contact Address:	Suvен Pharmaceuticals Limited 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai, Maharashtra, 400093	
Contact No.	+91 40 2354 9414	

The Board meeting concluded at 3.48 p.m. IST.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Suvен Pharmaceuticals Limited**

Kundan Kumar Jha
*Company Secretary, Compliance Officer
and Head-Legal*

Encl: as above

Suvен Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIIC, Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvенpharm.com | Website: www.suvенpharm.com | CIN: L24299MH2018PLC422236

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Annexure 1A

(1)	Name of the person	Mr. Vaidheesh Annaswamy
(2)	Reason for change viz. appointment, resignation, removal, death or otherwise	Mr. Vaidheesh Annaswamy has resigned from his position as Director and Executive Chairman of the Company, as he has decided to move to an advisory role, given the stage of his career.
(3)	Date of cessation	Effective from close of business hours on September 19, 2024
(4)	Brief Profile (in case of appointment)	Not applicable
(5)	Disclosure of relationship between directors (in case of appointment)	Not applicable

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236

Letter of Resignation

Dated: September 19, 2024

To:

Suven Pharmaceuticals Limited
215 Atrium, C Wing, 8th Floor, 819-821,
Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093,
Maharashtra, India

Attention: The Board of Directors

Sub: Resignation as Executive Chairman of the Company

I, Vaidheesh Annaswamy (DIN: 01444303) hereby:

1. tender my resignation from the office of the Executive Chairman and Director of Suven Pharmaceuticals Limited (the “**Company**”);
2. tender my resignation from all committees of the Board of Directors that I am a member and / or chairman of; and
3. surrender and irrevocably agree to revocation of all authority and power conferred on me in connection with the offices and positions set out in (1) and (2) above,

with effect from close of business hours on September 19, 2024 (the “**Effective Date**”).

I am tendering my resignation as I have decided to move to an advisory role, given the stage of my career and my life priorities.

I hereby confirm that, with effect from the Effective Date, I will cease to be an Executive Chairman and Director on the Board of Directors of the Company.

I hereby confirm that, I have no claims against the Company, and release the Company from any liability on and from the Effective Date, in each case in connection with my role as the Executive Chairman and Director on the Board of Directors of the Company.

I thank the Board of Directors of the Company for having given me the opportunity and assistance to discharge my duties during my tenure as Executive Chairman and Director of the Company.

Thanking you,

Yours sincerely,



Vaidheesh Annaswamy
(DIN: 01444303)

Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Annexure - 2A

(1)	Name of Director	Mr. Vivek Sharma
(2)	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment as Additional Director and Executive Chairman of the Company
(3)	Date of appointment & Term of appointment	With effect from September 20, 2024 Appointment by the Board of Directors on September 19, 2024, as an Additional Director and Executive Chairman of the Company, for a term of five years, with effect from September 20, 2024. The said appointment is subject to approval of the shareholders of the Company through Postal Ballot process.
(4)	Brief profile (in case of appointment)	Annexed as Annexure 2B
(5)	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Vivek Sharma is not related to any Director or Key Managerial Personnel of the Company.
(6)	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively.	We hereby confirm that Mr. Vivek Sharma is not debarred from holding the office of a Director by virtue of any SEBI Order or any other such authority.

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236

Annexure - 2B

Profile of Mr. Vivek Sharma



Vivek brings tremendous CDMO and leadership expertise to Suven Pharmaceuticals, acquired across his roles as CEO of Piramal Pharma solutions (2014-19) and as Chairman & CEO of Adare Pharma solutions, a technology CDMO business (2020-22). He was also CEO of Decision Resources Group, a healthcare analytics company (2019-20) and CEO of Saama, an AI clinical analytics company (2022-24). Vivek was recognized as ‘Global CEO of the Year’ by CPhI Pharma Awards in 2015. Based out of Boston, Vivek will help build a stronger customer connect and further drive global expansion of the platform. Vivek earned an Executive MBA from the Thunderbird School of Global Management. He is also a Chartered Accountant and a Certified Public Accountant (CPA).

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236